TREE NEWS update: Simcere Pharmaceutical announced that its co-developed Class 1 biologic, culerviveimab injection (brand name Yingmule), has been approved by China’s National Medical Products Administration. It becomes the first domestically developed long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV) in the country. The drug was developed in strategic partnership with Ruiyang (Shandong) Biopharmaceutical.
China’s First Long-Acting RSV Preventive Antibody Approved
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
11m ago
Trump Downplays Iran Conflict as ‘Small’ for US
34m ago
US Jobs Report Knocks Bitcoin Below $81,000
41m ago
CFTC: COMEX gold net longs fall to 4-week low
41m ago
CFTC: Speculators raise WTI net long positions to 12-week high
42m ago
US Treasury Secretary Bessent sees oil falling to $40 after Iran conflict
44m ago
CFTC: Speculators cut ultra-long bond net shorts by 36,734 contracts